Rxsight, INC Form 4 insider transactions

Aziz Mottiwala, President and CEO and a Director of RxSight, Inc., reported multiple transactions in common stock on July 24, 2026.

Robert Keith Warner, a Director at RxSight, Inc., acquired 37,037 shares of common stock on June 17, 2026, as per a Form 4 filing.

RxSight, Inc. reports that Director Robert J. Palmisano acquired 37,037 shares of common stock on June 17, 2026, as part of his compensation.

RxSight, Inc. Director Shweta Maniar acquired 37,037 shares of common stock through restricted stock units.

Director Tamara Fountain acquired 37,037 shares of common stock in RxSight, Inc. on June 17, 2026, as detailed in a Form 4 filing.

William J. Link, PhD, a Director at RxSight, Inc., has acquired 37,037 shares of common stock, increasing his beneficial ownership.

RxSight, Inc. Director Jesse Anderson Corley filed a Form 4 reporting the acquisition of 37,037 shares of common stock.

RxSight, Inc. Director Raymond W. Cohen acquired 30,864 shares of common stock on June 17, 2026, as part of an equity award.

Juliet Bakker, a Director at RxSight, Inc., has filed a Form 4 detailing transactions related to her beneficial ownership of company stock.

Julie Andrews, a Director at RxSight, Inc., has reported a transaction involving the acquisition of 37,037 shares of common stock.

RxSight Chief Operating Officer Ilya Goldshleger exercised options to acquire 12,489 shares of common stock.

RxSight's Chief Financial Officer, Mark Wilterding, reported the vesting of 20,441 Restricted Stock Units and a subsequent sale of 8,068 shares for tax withholding purposes.

RxSight Chief Customer Officer Scott Gaines reported recent acquisitions and dispositions of common stock and restricted stock units, including new RSU grants and vesting events.

RxSight, Inc. Chief Operating Officer Ilya Goldshleger received a grant of 32,218 restricted stock units, vesting over several years.

RxSight's Chief Business Development Officer, Eric Weinberg, was granted 32,218 restricted stock units, vesting over several years.

RxSight, Inc. President and CEO, Ronald M. Kurtz, MD, was granted 80,545 restricted stock units, vesting over several years.

RxSight, Inc. Chief Financial Officer Mark Wilterding received grants of 258,770 stock options and 163,528 restricted stock units, aligning his interests with long-term shareholder value.

RxSight's Co-President and COO, Ilya Goldshleger, exercised a significant number of stock options, acquiring common stock and increasing his direct beneficial ownership.

RxSight, Inc. Director Raymond W. Cohen was granted 35,668 restricted stock units (RSUs) effective July 31, 2025.

RxSight, Inc. Director William J. Link, Ph.D., was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of his compensation, aligning his interests with shareholders.

RxSight, Inc. Director Tamara Fountain was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of her compensation, aligning her interests with shareholders.

RxSight, Inc. Director Robert Keith Warner was granted 10,752 restricted stock units, increasing his direct beneficial ownership to 41,039 shares, signaling continued alignment with shareholder interests.

RxSight, Inc. Director Shweta Maniar was granted 10,752 restricted stock units (RSUs) as part of her compensation, aligning her interests with shareholders.

RxSight, Inc. Director Robert J. Palmisano was granted 10,752 restricted stock units (RSUs) on June 3, 2025, increasing his total beneficial ownership to 41,039 shares of common stock.

RxSight, Inc. Director Julie Andrews has acquired 10,752 Restricted Stock Units (RSUs), increasing her beneficial ownership in the company to 41,039 shares.

RxSight, Inc. Director Juliet Tammenoms Bakker is set to acquire 10,752 restricted stock units on June 3, 2025, as part of her compensation, with vesting contingent on continued service.

RxSight, Inc. Director Jesse Anderson Corley was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of his compensation, aligning his interests with shareholders.

Eric Weinberg, Co-President and Chief Commercial Officer of RxSight, Inc. (RXST), exercised stock options to acquire 188,002 shares of common stock at $3.93 per share, increasing his total beneficial ownership to 496,254 shares.

Shelley Thunen, CFO of RxSight, Inc., reports exercising stock options and acquiring common stock through the company's employee stock purchase plan.

Tamara Fountain, a director at RxSight, Inc., sold 7,000 shares of common stock on March 12, 2025, at a weighted average price of $25.7145, according to a Form 4 filing with the SEC.